Rilematovir

Summary

Rilematovir (CHEMBL4437054) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including respiratory syncytial virus infectious disease and liver disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 16
• Chemistry: 500.9 Da · C21H20ClF3N4O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4437054
Name	Rilematovir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	118892432
Molecular formula	C21H20ClF3N4O3S
Molecular weight	500.9
InChIKey	GTQTUABHRCWVLL-UHFFFAOYSA-N

SMILES: CS(=O)(=O)CCCN1C2=C(C=C(C=C2)Cl)C=C1CN3C4=C(C=CN=C4)N(C3=O)CC(F)(F)F

IUPAC name: 3-[[5-chloro-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)imidazo[4,5-c]pyridin-2-one

Also known as: Jnj-53718678, Rilematovir, RILEMATOVIR, JNJ678

Patent coverage: 62 distinct patent families (210 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 159 (76%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
respiratory syncytial virus infectious disease	2	MONDO:0001577	EFO:1001413
liver disorder	1	MONDO:0005154	EFO:0001421

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE1	8
PHASE2	6
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04583280	PHASE3	TERMINATED	A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
NCT02387606	PHASE2	COMPLETED	Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.
NCT03379675	PHASE2	COMPLETED	A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus
NCT03656510	PHASE2	TERMINATED	Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
NCT04056611	PHASE2	TERMINATED	Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
NCT04068792	PHASE2	COMPLETED	A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease
NCT04978337	PHASE2	TERMINATED	A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
NCT02593851	PHASE1	TERMINATED	A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
NCT02729467	PHASE1	COMPLETED	A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
NCT02945007	PHASE1	COMPLETED	A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation
NCT03002779	PHASE1	COMPLETED	A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants
NCT03696459	PHASE1	COMPLETED	A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants
NCT04090086	PHASE1	COMPLETED	A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants
NCT04332523	PHASE1	TERMINATED	A Study of JNJ-53718678 in Participants With Hepatic Impairment
NCT05155007	PHASE1	COMPLETED	A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir
NCT04221412	Not specified	NO_LONGER_AVAILABLE	Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).